Bioton S.A. Sees Up To $2 Bln From Bayer AG Insulin Deal

Bookmark and Share

WARSAW, July 9 (Reuters) - Polish drug maker Bioton BOTN.WA expects $1.5-$2.0 billion in revenues from the 15-year contract to allow Germany's Bayer AG (BAYG.DE) to distribute its insulin in China, it said in a statement on Thursday.

Back to news